# An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based Chemotherapy

> **NCT02538666** · PHASE3 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 907 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **BIOLOGICAL:** Nivolumab
- **BIOLOGICAL:** Ipilimumab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02538666
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10-13
- **Primary completion:** 2018-10-01
- **Final completion:** 2021-11-11
- **Target enrollment:** 907 (ACTUAL)
- **Last updated:** 2023-01-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02538666

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02538666, "An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based Chemotherapy". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02538666. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*